Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
about
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesClinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsPonatinib in refractory Philadelphia chromosome-positive leukemias.Current developments in molecular monitoring in chronic myeloid leukemiaCancer stem cells in basic science and in translational oncology: can we translate into clinical application?Drug Therapy in the Progressed CML Patient with multi-TKI FailureSecondary mutations as mediators of resistance to targeted therapy in leukemiaCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsIdentification of small molecules that disrupt signaling between ABL and its positive regulator RIN1Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Underdetermination in evidence-based medicine.Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasBosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Selecting the best frontline treatment in chronic myeloid leukemiaTyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Chronic Myelogenous Leukemia, Version 1.2014Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsManaging chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents.Best Practices in Chronic Myeloid Leukemia Monitoring and ManagementEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaDrug monographs: bosutinib and regorafenib.Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatmentLong-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
P2860
Q29938345-0F165E3F-1EA0-4028-9D23-49299F205F8BQ29938509-1C39E268-6BFD-4233-8166-7D40DE93446DQ29938515-0F76C429-10B5-492E-9513-6AEA72B9646EQ29938707-90AAC1F3-CC1C-48EA-8CA5-2E13AB064BD5Q32965008-BB4645E0-31AE-434C-8CDC-11CE7AD18698Q32965023-44AA5E59-A0F0-4EE0-9C29-919D12A47F63Q32965059-6EAC472F-2614-4448-A313-8DE502789AC4Q32965441-7326DA5C-5939-4C53-9C68-210F28CA6D05Q32965445-52D96737-AF03-4B21-8946-A4788A45812FQ56241029-9CD562EC-63D7-49BA-983D-3C9763EEDC1EQ56241031-7FE9F967-D3F5-41D7-ADD0-CF33512B88A4Q56241032-848A5167-DC03-43A7-A099-1FDCF7A23BA0
P1310
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
P248
Q24607114-C9EC6F73-47BC-427A-849D-974B5D4C2C4AQ26738514-F55C94BE-E699-438D-AD89-334F8CD9E35DQ26749324-A2EDD365-DE72-4B37-8EAB-C334B4A77BE8Q26768158-897662EE-085E-4AC3-B478-3C60707A33BEQ27004032-9A67E595-540B-4696-8F73-7EAA97FC9FE5Q27028181-494E46EA-962E-4089-A41A-BD562F6DF997Q27851967-B071364B-87E7-42CD-A290-A122930FE891Q28066148-01D2A95E-5EF4-4C34-8765-3760ACF457CFQ28081844-3C0BE77F-A82D-4714-B106-24B47E51D0EAQ28085353-6512E4FA-1EA4-4625-8E5D-20E3400C9EDCQ28087213-A5481758-A992-471E-B939-A79C56D43C54Q28484913-8481C4B7-171F-452A-AE13-B0E4E5C1408BQ28545055-F357CF94-6311-4A41-A3B7-C331991CCF24Q30242015-079648D7-40C0-41BB-B46E-33C94D2FD7B3Q30368763-9B15CC08-BD9D-4235-8A7C-B2C5935EA4CCQ33403826-5363C563-21A8-4933-B7A0-2FC51505EBD7Q33408049-E39D3F49-6F23-4C7A-A68F-4E7251B27020Q33408546-D9F0068C-DF20-4299-8492-8C3310DE211FQ33411250-5398D2F9-5F9E-463E-868D-F602C3D4E461Q33412495-F36775BD-CCFA-4C77-B206-2CCC9F38440DQ33414487-4090A579-087D-463E-8EDD-0BE8AA4EBD89Q33434675-3870B3C7-0EC4-4295-B0C2-81116D889222Q33442587-6A270594-47C9-453E-9185-97F157FC9708Q33764253-1F2A0971-1C8C-4112-9F57-FBAFC1E4BF67Q34272962-EE9C43E4-1264-41F8-A8D6-55F033868CBAQ34297594-FF237D7E-BB2C-4F80-935A-6C31AE565567Q34522810-3808C9E7-E8C8-4822-9FAB-02668148F304Q34763374-596FF855-3ADB-448C-A256-10893D4A220AQ35008618-92425514-9A0A-4776-813B-F74E86210E02Q35025461-16734950-4E15-46C8-B951-F696DDFDDF08Q35743878-4EF281AA-E4FA-454B-AA6D-D81DA38D9D80Q36355098-FBC02A5F-B99C-4908-A324-BDBEE966C2B0Q36364850-F457F8A2-216D-4EFD-8AF0-58EF672421F6Q36808017-0AB230F6-5A3E-43C8-8CEB-3E3DACDF4C4CQ36884361-5E0EDA6F-D019-4E48-B894-DA40F66586FEQ37026032-77F9935F-DE84-4E49-B311-832E424C06DCQ37117967-2F9536C2-6529-416A-87CE-A6666CE288C1Q37340111-537DF95E-D584-40D9-9029-C5DB717F8BE8Q37366251-DED31BE7-F7C4-4655-8B8C-0A862F283E65Q37461942-8D71DF68-65A9-4065-8166-E0D0B22B6AFD
P2860
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 February 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bosutinib is active in chronic ...... d/or nilotinib therapy failure
@en
Bosutinib is active in chronic ...... /or nilotinib therapy failure.
@nl
type
label
Bosutinib is active in chronic ...... d/or nilotinib therapy failure
@en
Bosutinib is active in chronic ...... /or nilotinib therapy failure.
@nl
prefLabel
Bosutinib is active in chronic ...... d/or nilotinib therapy failure
@en
Bosutinib is active in chronic ...... /or nilotinib therapy failure.
@nl
P2093
P2860
P50
P921
P1433
P1476
Bosutinib is active in chronic ...... d/or nilotinib therapy failure
@en
P2093
Andrey Zaritskey
Athena Countouriotis
Dong-Wook Kim
H Jean Khoury
Nadine Besson
Tim H Brümmendorf
Virginia Kelly
P2860
P304
P356
10.1182/BLOOD-2011-11-390120
P407
P577
2012-02-27T00:00:00Z